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Background: Allogeneic hematopoietic stem cell transplantation with HLA-identical donors has been
established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of
50% to 60%.
Objectives: To analyze the overall survival of patients and identify factors that influence the outcomes
of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan
combination as conditioning regimen.
Methods: Twenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003
and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine
and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment
time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal
obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host
disease and one extensive chronic graft-versus-host disease.
Results: The overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau
at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an
improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value =
0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five
due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graft-
versus-host disease and three relapses followed by renal failure (one) and infection (two). The cause
of death could not be determined for two patients.
Conclusion: The busulfan and melphalan conditioning regimen is as good as other conditioning
regimens providing an excellent survival rate.
Keywords: Stem cell transplantation; Leukemia, myeloid, acute; Drug toxicity; Bone marrow
transplantation;  Busulfan/administration & dosage; Combined modality therapy; Cyclophosphamide/
administration & dosage; Graft vs. Host disease;  Survival analysis; Prognosis
Introduction
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) with a HLA-identical
donor has been established to treat acute myeloid leukemia (AML) patients for more than
30 years and can cure 50% to 60% of patients.(1) In young patients, with intermediate
cytogenetic risk after first complete remission (1st CR), the risk of recurrence is generally
less than 20%, but this favorable effect is partly hampered by the toxicity of the procedure,
infectious complications and graft-versus-host disease (GvHD). As a result, Allo-HSCT
has limited gain in survival despite the low rate of relapse.(2-4)
There is a great difference in the risk of relapse in AML patients according to cytogenetic
alterations. After 1st CR, young patients with intermediate or unfavorable cytogenetic risk,
have relapse rates of 50% and 80% respectively. In these patients, Allo-HSCT as the first line
may represent the best option to prevent relapse, but this depends on the availability of a
HLA-matched donor.(2-4) The French-American-British (FAB) classification(5-7) has frequently
been used to stratify the degree of risk in combination with cytogenetic alterations.(8-11)
The use of a cyclophosphamide (Cy) and busulfan (BU)(12,13) combination is the
most used conditioning for Allo-HSCT, followed by total body irradiation combined with
Cy.(14) The association of busulfan and melphalan (BU/Mel)(15-17) is the most used regimen
in this service in order to decrease the incidence of hematuria associated with Cy as
these agents are active in the treatment of AML.
This study aimed to analyze the overall survival in Allo-HSCT with HLA-identical
donors of AML patients in 1st CR who received the BU/Mel combination, to identify factors
that influenced the overall survival, to evaluate the toxicity of the conditioning regimen and
to determine the causes of death.
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 Methods
From October 11, 2003 to February 22, 2008, 25 consecutive
patients with AML in 1st CR submitted to Allo-HSCT were
analyzed retrospectively. The study was closed on March 31,
2009. The study project was submitted and accepted by the
Institution's Review Committee on Research Projects and all
patients were informed about the nature of the project, signed
consent forms and voluntarily participated in the study.
The series is comprised of 13 male and 12 female
patients. The median age at time of transplant was 34 years
with the youngest being 16 and the oldest 57 years old.
Nineteen were Caucasian and six non-Caucasian. Five
patients had a history of myelodysplastic syndromes and
two had previously received chemotherapy for lupus
erythematosus and glioma.
Cytogenetic analysis was performed in 15 patients; one
was believed to have a good prognosis, eight intermediate
prognoses and six bad. According to the French-American-
British (FAB) classification three patients were classified with
subtype M1, four M2, one M3, two M4, four M5, two M6,
one M7, seven secondary and one biphenotypic.
Twenty patients were induced with a chemotherapy
protocol consisting of arabinoside (Ara-C) for seven days
and anthracycline for three days (3 + 7). Five received other
induction protocols. Intensive consolidation chemotherapy
with high-dose Ara-C (HD Ara-C) was performed in 16 patients,
while nine did not receive it.
After the first cycle of chemotherapy, nine of 16
achieved CR. This information is unavailable for nine patients
as they were referred to the service and the information was
lacking at referral.
The median transfusion of concentrated red blood cells
before transplantation in 13 patients was 9 U (Range: 0 - 24 U).
Four patients, with a median of 6 U, received platelets by
apheresis (AP). Multiple donor platelets (MDP) were infused
in ten patients with a median of 27 U (Range: 5 - 197 U). Data on
the number of previous transfusions in other patients are
unavailable either because they received multiple transfusions
or because the information was lacking at referral.
Donor and histocompatibility system (HLA)
Of the 25 transplant patients with HLA-identical related
donors, 17 donors were male and eight female. Comparative
analysis of donor/recipient showed that 15 donors were of
the same gender as the patient (five females and ten males)
and ten were of different genders (six female patients with
male donors and four male patients with female donors).
The median donor age was 35 years old (Range: 14 - 62
years). Data on pregnancy, childbirth and miscarriages of
female donors showed that only two donors had had children.
The source of the infused cells was bone marrow (BM)
from twenty HLA-identical donors and peripheral stem cells
(PSC) after mobilization with filgrastim from five. The
median number of total cells infused into twenty patients
was 2.7 x 108/kg (Range: 0.9 to 18.4 x 108/kg). In seven donors the
median of CD34+ was 5.7 x 106 /kg (Range: 1.5 to 10.0 x 106 /kg).
The characteristics of transplant patients are shown in
Table 1.
Conditioning regimen
Patients were conditioned with busulfan 16 mg/kg
(1 mg/kg orally every six hours on days -7 to -4) and melphalan
140 mg/m2 intravenously on the day before transplantation
(BU/Mel).
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Prophylaxis
All patients received 10 mg/kg/day of diphenylhydantoin
orally, split in four doses to prevent seizures. To prevent
infection, patients received trimethoprim-sulfamethoxazole,
cefepime, fluconazole and acyclovir, even after engraftment.
All patients received cyclosporine and methotrexate as
prophylaxis against chronic GvHD.
Statistical analysis
The statistical analysis considered death as the event
of interest. The estimated cumulative probability of survival
was made by estimating the Kaplan-Meier product limit and
making comparisons between curves using the log-rank test.
Descriptive statistical analysis was made of follow-up time
of surviving patients until March 21, 2009. In every analysis
we adopted a significance level (p) of 5%.(18)
Patients were evaluated respectively, were in 1st CR, and
the indication of Allo-HSCT was due to the existence of HLA-
identical donors. We analyzed engraftment, toxicity related
to conditioning regimen, while the outcome of the study was
overall survival (OS) and associated risk factors.
Definitions
CR is the absence of blasts in peripheral blood, less
than 5% blasts in bone marrow, lack of evidence of extra-
medullar leukemia or absence of disease recurrence.
Transplant related mortality and relapse was the
recurrence of the disease at any time after transplantation.
OS is survival at the end of the follow up period.
Granulocyte engraftment is the presence of more than
0.5 x 109/L granulocytes in blood counts on three consecutive
days. Platelet engraftment is the presence of more than 20 x
109/L platelets for more than seven days without the need of
a platelet transfusion. Follow-up time was calculated as the
interval between the date of transplant until the date of death,
or until March 31, 2009, for those who survived until the end
of the follow up period.
The criteria used were those of the FAB classification,(5,6)
cytogenetic risk(9,10) and toxicity of the World Health
Organization (WHO).(19)
Results
Of the 25 patients, the median time between diagnosis
and transplantation was 191 days (Range: 73 - 651 days). The
median follow up of patients was 768 days (Range: 15 - 5645
days).
The median granulocyte engraftment time was 16
days for 21 patients evaluated with the granulocyte count
higher than 0.5 x 109/L (Range: 7 - 22 x 109/L). The median
platelet engraftment time was 15 days for a count higher
than 20 x 109/L (Range: 0 - 56 x 109/L) in 21 patients and for
a count higher than 50 x 109/L (Range: 7 - 46 x 109/L) it was 17
days in 19 patients.
The median transfusion after Allo-HSCT for filtered and
irradiated concentrated red blood cells in 21 patients was
5.5 U (Range: 1 - 26 U), for aphaeresis in seven patients it was
17 U (Range: 1 - 18 U) and for multiple donor platelets in eight
patients it was 20.5 U (Range: 7 - 60 U).
Infections occurred in all 25 patients including 12
episodes of infection of undetermined origin, six infections
by gram-negative bacteria, two gram-positive, 11 viral and
five fungal infections. The antigenemia was positive for
cytomegalovirus (CMV) in 11 patients and the event occurred
from day +25 to day +62 with a median positivity at around
day +37.
Sinusoidal obstructive syndrome (SOS) was observed
in three patients on days +7, +10 and +10. Hematuria occurred
in two patients. Moderate to severe mucositis occurred in 17
patients, nausea and vomiting in eight and diarrhea in seven.
The others did not report these symptoms or only had a mild
form of the disease.
Acute GvHD was absent in six patients, six had grade I,
seven had grade II and two grade III. Four patients were not
evaluated for acute GvHD. Four patients did not have chronic
GvHD, 14 had mild chronic GvHD and one had extensive
chronic GvHD. Six patients were not assessed for chronic
GvHD. Analyses of engraftment, toxicity, and acute and
chronic GvHD are shown in Tables 2, 3 and 4.
The overall survival rate was 47% after 36 months; 12
patients survived without disease to the end of the study.
Descriptive statistics of the patients that survived after the
study showed a median survival of 2073 days (Range: 403 -
5645 days).
The probability of survival according to the Kaplan-
Meier method showed no significant differences in relation
to gender, FAB classification of leukemia, cytogenetic
analysis, induction therapy, remission after the 1st induction
cycle and source of infused cells (PSC or BM). There were
statistically significant differences in relation to intensive
consolidation and acute and chronic GvHD; the probability
of survival at 36 months of patients who received intensive
consolidation with HD Ara-C was 73% and patients who did
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Figure 1 - Overall survival of AML patients in 1st complete remission,
conditioned with a BU/Mel combination and submitted to allogeneic
hematopoietic stem cell transplantation - survival associated to
intensive consolidation
not receive consolidation did not survive. Six of seven
patients who presented with grade II acute GvHD or the lack
of or limited chronic GvHD had a better chance of survival
with a probability of survival of 50% and 66.6%, respectively.
The patient with extensive chronic GvHD had died by 12
months.
Table 5 presents the probability of survival at 12, 24
and 36 months in respect to different variables and statistical
significance. The survival curves of intensive consolidation
with HD Ara-C, acute and chronic GvHD and overall survival
are shown in Figures 1, 2, 3 and 4, respectively.
The cause of death of five of 13 patients who died was
infection within 100 days of transplantation; three patients
died due to relapse on days +189, +274 and +917 followed by
renal failure for one and infection for the other two; one had
an alveolar hemorrhage on day +18 and one coagulopathy
on day +974 after a second mini-allogeneic transplantation.
One patient died of chronic GvHD and CMV on day +164. It
was not possible to determine the cause of death for two
patients (days +103 and +185) as this data was not recorded
on their charts.
Of the patients who died after relapse, two had
myelodysplastic syndrome before AML, and one had had
glioma and had been submitted to chemotherapy before the
diagnosis of AML. Cytogenetic analysis after death was
normal in three patients; two had trisomy of chromosome 8,
five had complex rearrangements and cytogenetics was not
performed in three.
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Discussion
Allo-HSCT is the therapy of choice for AML.(20,21)
However there are limitations to the applicability of
transplantation in most patients, including difficulties in
controlling the disease with the initial induction, the lack of
HLA-identical donors, toxicity of the conditioning regimen
and long-term complications arising from it.
In this study, 25 patients with AML in 1st CR who
underwent Allo-HSCT received the busulfan and melphalan
combination as the conditioning regimen. Analysis of
gender, induction therapy and CR after 1st cycle of induction
chemotherapy showed no statistical significance on
survival. However, 73% of patients submitted to intensive
consolidation with HD Ara-C survived to the end of the
study but all of those who did not receive consolidation
died (p-value = 0.0001). The procedure benefited patients
with favorable or unknown cytogenetics and good and bad
prognoses according to the FAB classification. Despite the
small number of patients, our results, unlike the literature,(22)
show the benefits of intensive consolidation in patients
undergoing this type of transplant.
Most patients had severe mucositis, nausea and
vomiting. SOS only occurred in three (12%) patients a lower
rate than reported in publications.(23) Hematuria occurred in
two patients. All patients had post-transplant infection and
CMV antigenemia was present in 44%. The median
engraftment time did not differ from published data.(24,25)
The survival rate was around 47%, with 12 of the 25
patients alive without disease, similar to that observed in the
literature.(1,3,4,26) Moreover, survival leveled off according to
the Kaplan-Meier method 36 months after the procedure. A
period when survival leveled off was reported in another
study(27) on autologous transplants after 24 months.
In this study, patients with grade II acute GvHD had a
survival rate of 85.7%, that is better than other patients, which
can be explained by the graft versus leukemia effect in this
type of transplant.(14) Limited chronic GvHD was observed in
15 patients and one, who presented extensive chronic GvHD,
died on day +164 post-transplant.
Of the 13 patients who died, five deaths were due to
infection, all within 100 days post-transplant, three due to
relapse, one to infection and chronic GvHD, two to bleeding
and for two it was not possible to determine the cause of
death.
Conditioning with the BU/Mel combination(15-17) is most
used in our service as these agents are active in the treatment
of AML but cause less hematuria. The conclusion in this
study is that Allo-HSCT in AML patients in 1st CR showed
similar results to the literature.(1,3,4,26) Patients who received
intensive consolidation with HD Ara-C post-induction had
better survival than the others. Hence, prospective studies
should be performed in Brazil to assess the importance of
intensive consolidation in this type of procedure. Acute and
chronic GvHD were important in the survival of patients thus
Figure 4 – Overall survival of AML patients in 1st complete remission,
conditioned with a BU/Mel combination and submitted to allogeneic
hematopoietic stem cell transplantation
Figure 3 – Overall survival of AML patients in 1st complete remission,
conditioned with a BU/Mel combination and submitted to allogeneic
hematopoietic stem cell transplantation – survival associated to chronic
graft-versus-host disease
Figure 2 – Overall survival of AML patients in 1st complete remission,
conditioned with a BU/Mel combination and submitted to allogeneic
hematopoietic stem cell transplantation – survival associated to acute
graft-versus-host disease
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supporting published data.(14,28,29) The BU/Mel conditioning
regimen(15-17) proved to be a valid alternative to BU/Cy(12,13)
as it decreases the incidence of hemorrhagic cystitis and
provides a good survival rate.
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